Canadian Cancer Trials Group Bulletins


Recent Publication

A publication related to LY.9 -- Randomized Intergroup Trial of First Line Treatment for Patients with Diffuse Large B-Cell Non-Hodgkins Lymphoma with a CHOP-like Chemotherapy Regimen with or without the Anti-CD20 Antibody Rituximab (IDEC-C2B8) -- was recently published in The Lancet Oncology.

Pfreundschuh M, Kuhnt E, Trümper L, Ősterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, for the MabThera International Trial (MinT) Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. The Lancet Oncology 12: 1013-22, 2011.